Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.

Barrett A, Debackere N, Ribeiro A, Keapoletswe K, Zingel R, Coles B

Advances in therapy7 Jun 2023Cited by 4 (Europe PMC)

PMID37286889PMCIDPMC10246869DOI10.1007/s12325-023-02540-yPepBankPUB-37286889

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In German adults with T2DM, 65.6% of incident dulaglutide users received 1.5 mg at 12 months.
In plain wordsIn German prescription records, 1.5 mg was the most common dulaglutide dose among incident users.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGerman incident-user dose distribution
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
65.6%
Germany, cohort 1 (incident users), dulaglutide 1.5 mg at 12 months post-index
Source sentences
Summary
Among dulaglutide users in Germany at 12 months post-index, the 1.5-mg dosage formulation was the most common for both cohort 1 (65.6%) and 2 (71.2%).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3728688901
02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In German adults with T2DM, 71.2% of prevalent dulaglutide users received 1.5 mg at 12 months.
In plain wordsIn German prescription records, 1.5 mg was the most common dulaglutide dose among prevalent users.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGerman prevalent-user dose distribution
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
71.2%
Germany, cohort 2 (prevalent users), dulaglutide 1.5 mg at 12 months post-index
Source sentences
Summary
Among dulaglutide users in Germany at 12 months post-index, the 1.5-mg dosage formulation was the most common for both cohort 1 (65.6%) and 2 (71.2%).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3728688902
03HumanNot a test of Semaglutide aloneObservational studyOther
Among German incident subcutaneous semaglutide users, 39.2% received 0.5 mg at 12 months.
In plain wordsIn German prescription records, 39.2% of incident semaglutide users received the 0.5 mg formulation.
Peptide
Semaglutide
Outcome
Not applicableGerman incident-user 0.5 mg prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
39.2%
cohort 1, 0.5 mg
Source sentences
Summary
Among s.c. semaglutide users at 12 months post-index, 39.2% and 58.4% of cohort 1 received 0.5 mg and 1.0 mg, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3728688903
04HumanNot a test of Semaglutide aloneObservational studyOther
Among German incident subcutaneous semaglutide users, 58.4% received 1.0 mg at 12 months.
In plain wordsIn German prescription records, 58.4% of incident semaglutide users received the 1.0 mg formulation.
Peptide
Semaglutide
Outcome
Not applicableGerman incident-user 1.0 mg prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
58.4%
Germany, cohort 1 (incident users), s.c. semaglutide 1.0 mg at 12 months post-index
Source sentences
Summary
Among s.c. semaglutide users at 12 months post-index, 39.2% and 58.4% of cohort 1 received 0.5 mg and 1.0 mg, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3728688904
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Among UK incident dulaglutide users, 71.7% received 1.5 mg at 12 months.
In plain wordsIn UK prescription records, 1.5 mg was the most common dulaglutide dose among incident users.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableUK incident-user dose distribution
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
71.7%
UK, cohort 1 (incident users), dulaglutide 1.5 mg at 12 months post-index
Source sentences
Summary
In the UK, at 12 months post-index, the most common dulaglutide dosage formulation was 1.5 mg (71.7% cohort 1 and 80.9% cohort 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3728688905
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Among UK prevalent dulaglutide users, 80.9% received 1.5 mg at 12 months.
In plain wordsIn UK prescription records, 1.5 mg was the most common dulaglutide dose among prevalent users.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableUK prevalent-user dose distribution
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
80.9%
UK, cohort 2 (prevalent users), dulaglutide 1.5 mg at 12 months post-index
Source sentences
Summary
In the UK, at 12 months post-index, the most common dulaglutide dosage formulation was 1.5 mg (71.7% cohort 1 and 80.9% cohort 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3728688906
07HumanNot a test of Semaglutide aloneObservational studyOther
Among UK incident subcutaneous semaglutide users, 38.9% received 0.5 mg at 12 months.
In plain wordsIn UK records, 38.9% of incident semaglutide users received the 0.5 mg formulation.
Peptide
Semaglutide
Outcome
Not applicableUK incident-user 0.5 mg prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
38.9%
UK, cohort 1 (incident users), s.c. semaglutide 0.5 mg at 12 months post-index
Source sentences
Summary
Among s.c. semaglutide users at 12 months post-index, 0.5- and 1.0-mg formulations were the most common for both cohort 1 (38.9% and 56.0%, respectively) and cohort 2 (29.5% and 67.1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3728688907
08HumanNot a test of Semaglutide aloneObservational studyOther
Among UK incident subcutaneous semaglutide users, 56.0% received 1.0 mg at 12 months.
In plain wordsIn UK records, 56.0% of incident semaglutide users received the 1.0 mg formulation.
Peptide
Semaglutide
Outcome
Not applicableUK incident-user 1.0 mg prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
56%
UK, cohort 1 (incident users), s.c. semaglutide 1.0 mg at 12 months post-index
Source sentences
Summary
Among s.c. semaglutide users at 12 months post-index, 0.5- and 1.0-mg formulations were the most common for both cohort 1 (38.9% and 56.0%, respectively) and cohort 2 (29.5% and 67.1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3728688908
09HumanNot a test of Semaglutide aloneObservational studyOther
Among UK prevalent subcutaneous semaglutide users, 29.5% received 0.5 mg at 12 months.
In plain wordsIn UK records, 29.5% of prevalent semaglutide users received the 0.5 mg formulation.
Peptide
Semaglutide
Outcome
Not applicableUK prevalent-user 0.5 mg prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
29.5%
UK, cohort 2 (prevalent users), s.c. semaglutide 0.5 mg at 12 months post-index
Source sentences
Summary
Among s.c. semaglutide users at 12 months post-index, 0.5- and 1.0-mg formulations were the most common for both cohort 1 (38.9% and 56.0%, respectively) and cohort 2 (29.5% and 67.1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3728688909
10HumanNot a test of Semaglutide aloneObservational studyOther
Among UK prevalent subcutaneous semaglutide users, 67.1% received 1.0 mg at 12 months.
In plain wordsIn UK records, 67.1% of prevalent semaglutide users received the 1.0 mg formulation.
Peptide
Semaglutide
Outcome
Not applicableUK prevalent-user 1.0 mg prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Measurements
Proportion
67.1%
UK, cohort 2 (prevalent users), s.c. semaglutide 1.0 mg at 12 months post-index
Source sentences
Summary
Among s.c. semaglutide users at 12 months post-index, 0.5- and 1.0-mg formulations were the most common for both cohort 1 (38.9% and 56.0%, respectively) and cohort 2 (29.5% and 67.1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with evidence of T2DM and a prescription of dulaglutide or semaglutide between August 2020 and December 2021 were identified using the IQVIA Longitudinal Prescription Data (LRx).
Summary · context
Patients were divided into cohort 1 (incident users) and cohort 2 (prevalent users) based on previous exposure to GLP-1 RAs and were followed up to 12 months post-index.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3728688910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.